In an end‑stage renal disease patient who is nil per os (NPO) and hypoglycemic, what dextrose concentration and infusion rate should be used?

D5W for Hypoglycemia in ESRD Patient on NPO Status

For an ESRD patient who is NPO and hypoglycemic, administer 10-20 grams of IV dextrose (20-40 mL of 50% dextrose or 100-200 mL of 10% dextrose) titrated to the initial glucose value, then monitor blood glucose every 15 minutes with repeat dosing as needed to maintain glucose >70 mg/dL. 1, 2

Immediate Treatment Protocol

Stop any insulin infusion immediately and administer dextrose based on the severity of hypoglycemia 1:

• For glucose <70 mg/dL: Give 10-20 g IV dextrose
• Titrate the dose using the formula: (100 - blood glucose) × 0.2 g 1
• Preferred formulations:
  • 10% dextrose in 50 mL aliquots (5 g each) 1
  • 50% dextrose 10-25 g (20-50 mL) 2

Recheck glucose in 15 minutes and repeat dextrose administration as needed until glucose >70 mg/dL 1

Why ESRD Patients Are High-Risk

ESRD patients face a 14-fold increased risk of hypoglycemia during renal replacement therapy 1. The pathophysiology includes:

• Impaired insulin clearance (normally 30-80% cleared by kidneys) 3
• Reduced renal gluconeogenesis 3
• Altered glucose metabolism during dialysis 3
• NPO status increases risk 6.6-fold 1

Mortality from hypoglycemia in ESRD reaches 30% at admission or during hospitalization 3, making aggressive prevention and treatment critical.

Dextrose Concentration Selection

10% dextrose is preferred over 50% dextrose for several reasons 1, 4:

• Fewer adverse events: 0% vs 4.2% with D50 4
• Better post-treatment glucose control: Mean 6.2 mmol/L vs 8.5 mmol/L 4
• Avoids overcorrection: Prevents rebound hyperglycemia 1
• Safer administration: Reduces risk of cardiac arrest and hyperkalemia from rapid concentrated dextrose 1

However, 50% dextrose is acceptable when rapid correction is needed 2. The FDA-approved dose for insulin-induced hypoglycemia is 10-25 g (20-50 mL of 50% dextrose) 2.

Ongoing Management for NPO Patients

Once acute hypoglycemia is corrected:

Continuous dextrose infusion may be necessary 5:

• Start D5W or D10W at maintenance rate
• Monitor glucose every 1-2 hours 1
• Target glucose 150-200 mg/dL in ESRD patients 3

For refractory hypoglycemia during dialysis, consider modified dialysate 6:

• 2.5% dextrose-containing replacement fluid
• Y-connect 5% dextrose with 0.9% saline at appropriate ratios
• This approach resolved recalcitrant hypoglycemia in case reports 6

Critical Pitfalls to Avoid

1. Do not use D5W alone for acute treatment - insufficient concentration for rapid correction 1, 2

2. Avoid 25 g bolus doses in ESRD - causes excessive glucose elevation (14-170 mg/dL increase in 10 minutes) 1

3. Do not administer 50% dextrose rapidly - associated with cardiac arrest and hyperkalemia 1

4. Avoid glucagon in ESRD - delayed response (140 minutes to peak effect) and less effective 1

5. Monitor for recurrence - 76% of ESRD patients develop moderate hypoglycemia (<60 mg/dL) and 29% severe hypoglycemia (<40 mg/dL) during insulin therapy 7

Prevention Strategy

Reduce insulin doses by 25-50% in ESRD patients who are NPO 8, 9:

• Basal insulin: reduce by 25% on dialysis days 9
• Total daily dose: reduce by 50% in severe renal impairment 10
• Consider switching to agents with lower hypoglycemia risk (DPP-4 inhibitors, repaglinide) 3

Maintain glucose monitoring every 2-4 hours while NPO 5, with more frequent checks (every 1-2 hours) if on insulin infusion 1.